SCHEMBL385519

SCHEMBL385519

[CH]1CCC(C2CCCCC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
SLC18A3 Q16572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465040 0.97 ALDH1A1 (0.50) ALDH1A1SLC18A3
SCHEMBL164544 0.97 ALDH1A1 (0.57) ALDH1A1
SCHEMBL1415394 0.88 ALDH1A1 (0.47) ALDH1A1
SCHEMBL386067 0.88 ALDH1A1 (0.47) ALDH1A1
SCHEMBL1132982 0.86 ALDH1A1 (0.36) ALDH1A1
SCHEMBL8922551 0.85 ALDH1A1 (0.44) ALDH1A1
SCHEMBL56058 0.84 ALDH1A1 (0.50) ALDH1A1
SCHEMBL11501635 0.84 ALDH1A1 (0.50) ALDH1A1
SCHEMBL8921838 0.84 ALDH1A1 (0.50) ALDH1A1
SCHEMBL8558475 0.84 ALDH1A1 (0.50) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024094125-A1 LIPID COMPOUNDS, LIPID NANOPARTICLES, AND PHARMACEUTICAL COMPOSITIONS Shanghai Circode Biomed Co., Ltd. (CN) 2024-05-10 WO claimed
US-20100152176-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-17 US claimed
US-7696201-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-13 US claimed
EP-2051712-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmceuticals Incorporated (US) 2009-04-29 EP claimed
US-20080176843-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-07-24 US claimed
WO-2008021375-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-02-21 WO claimed
EP-1817032-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-08-15 EP claimed
US-20070089604-A1 Novel chromatographic stationary phase AGILENT TECHNOLOGIES, INC. 2007-04-26 US claimed
US-20070090052-A1 Chromatographic stationary phase AGILENT TECHNOLOGIES, INC. 2007-04-26 US claimed
US-20060287303-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2006-12-21 US claimed
EP-0194525-B1 N-CARBAMOYL-AZOLES AND FUNGICIDES CONTAINING THEM BASF Aktiengesellschaft (DE) 1988-08-10 EP claimed
EP-0275077-A1 Anthraquinone compounds and polarizing film containing the same MITSUBISHI KASEI CORPORATION (JP) 1988-07-20 EP claimed
EP-0269041-A2 Fungicidal cyclohexylamines BASF Aktiengesellschaft (DE) 1988-06-01 EP claimed
EP-0243449-A1 CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN THE UPJOHN COMPANY (US) 1987-11-04 EP claimed
WO-1987002367-A2 CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN THE UPJOHN COMPANY (US) 1987-04-23 WO claimed
EP-0194525-A2 N-Carbamoyl-azoles and fungicides containing them BASF Aktiengesellschaft (DE) 1986-09-17 EP claimed
US-4507221-A Anthraquinone dye and liquid crystal composition containing the same MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1985-03-26 US claimed
EP-0120463-A2 Anthraquinone dyes and liquid crystal compositions including the same HITACHI, LTD. (JP) 1984-10-03 EP claimed
US-4419263-A Liquid crystalline cyclohexylcarbonitrile derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-12-06 US claimed
US-4324455-A CONTAINING A QUINOPHTHALONE DYE MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1982-04-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176843-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 ALDH1A1 2356/4885SLC18A3 112/4885
US-20060287303-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 ALDH1A1 2356/4885SLC18A3 112/4885
US-20100152176-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 ALDH1A1 2356/4885SLC18A3 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.